Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET

Company Participants

Pia Eaves - Vice President-Investor Relations and Strategy
Terry Rosen - Chief Executive Officer
Jennifer Jarrett - Chief Operating Officer
Bob Goeltz - Chief Financial Officer
Dimitry Nuyten - Chief Medical Officer
Juan Jaen - President

Conference Call Participants

Yigal Nochomovitz - Citi
Jonathan Miller - Evercore ISI
Peter Lawson - Barclays
Asthika Goonewardene - Truist
Daina Graybosch - Leerink Partners
Jason Szymanski - Bank of America
Eva Fortea - Wells Fargo Securities

Operator

Good afternoon, thank you for attending today's Arcus Biosciences Third Quarter 2024 Earnings Call. My name is Tamiya and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call, with an opportunity for questions and answers at the end. [Operator Instructions]

I would now like to pass the conference over to your host, Pia Eaves, Vice President of Investor Relations. You may proceed.

Pia Eaves

Hello, everyone, and thank you for joining us on today's conference call to discuss Arcus' third quarter 2024 financial results and pipeline updates, including our upcoming presentation of [Indiscernible]. I'd like to remind you that on this call management will make forward looking statements, including statements about our cash runway and our expected clinical development milestones and timelines.

All statements, other than historical facts, reflect the current beliefs and expectations of management and involve risks and uncertainties that may cause our actual results to differ from those expressed. Those risks and uncertainties are described in our most recent quarterly report on Form 10-Q that has been filed with the SEC.

Today, you'll hear from our CEO, Terry Rosen; CMO, Dimitry Nuyten, COO, Jennifer Jarrett; and CFO, Bob Goeltz. We'll also be joined by our President Juan Jaen for questions after the prepared remarks.

With that, I'll turn the call over to Terry.

Terry Rosen

Thank you very much Pia and thank you all for joining us today. As we head in into 2025, our highest priority is to launch our late stage development program for our HIF-2 alpha inhibitor Casdatifan. As you know, just two weeks ago we presented initial data from our ARC-20 study evaluating cas in late-line clear-cell RCC in an oral plenary session at the ENA meeting. These data clearly validate our conviction that cas will be a best-in-class HIF-2 alpha inhibitor demonstrating improvement in every key efficacy measure that we analyze versus belzutifan. As you know, belzutifan is the only HIF-2 alpha inhibitor on the market today. So let's go to slide five and I'll recap the highlights from our data set.